Relapsed Or Refractory Pediatric Low Grade Glioma Lgg Harboring A Braf V600 Mutation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsed or refractory pediatric low grade glioma lgg harboring a braf v600 mutation. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

Originators in Relapsed Or Refractory Pediatric Low Grade Glioma Lgg Harboring A Braf V600 Mutation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsed or refractory pediatric low grade glioma lgg harboring a braf v600 mutation. Each bar = one year. Y-axis scaled to peak year (2 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Relapsed Or Refractory Pediatric Low Grade Glioma Lgg Harboring A Braf V600 Mutation — full disease profile
• AI Patent Landscape Report — type "relapsed or refractory pediatric low grade glioma lgg harboring a braf v600 mutation" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner